Jazz Pharmaceuticals (JAZZ) Long-Term Deferred Tax (2012 - 2026)

Jazz Pharmaceuticals' Long-Term Deferred Tax history runs 15 years deep, the most recent figure standing at $907.0 million for Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 57.71% year-over-year to $907.0 million in Q1 2026; TTM through Mar 2026 was $907.0 million, a 57.71% increase from a year earlier, with the FY2025 full-year figure at $869.1 million, up 55.13% from the prior year.
• Long-Term Deferred Tax rose to $907.0 million in Q1 2026 per JAZZ's latest filing, from $869.1 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $907.0 million in Q1 2026 and bottomed at $314.7 million in Q1 2022.
• The 5-year median for Long-Term Deferred Tax is $507.7 million (2024), against an average of $535.0 million.
• Across the five-year window, Long-Term Deferred Tax gained 0.1% in 2022 and soared 57.71% in 2026, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $376.2 million in 2022, then climbed by 27.0% to $477.8 million in 2023, then rose by 17.25% to $560.2 million in 2024, then surged by 55.13% to $869.1 million in 2025, then gained by 4.36% to $907.0 million in 2026.
• Per Business Quant, the three latest JAZZ Long-Term Deferred Tax figures stand at $907.0 million (Q1 2026), $869.1 million (Q4 2025), and $846.2 million (Q3 2025).